Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination~* BMI 25-45 kg/m\^2~* HbA1c between 7.5 % and 12.0 %, inclusive~Exclusion Criteria:~* Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening~* Patients previously treated with AC2993~* Patients presently treated with insulin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AC2993 (Type: EXPERIMENTAL): 5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period

Based on this trial design, predict the completion outcome and termination type (if applicable).